Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States
GLP-1 Weight Loss for Insulin Resistance and Metabolic Health Many patients interested in GLP-1 therapy also struggle with insulin resistance, prediabetes, type 2 diabetes risk, abdominal weight gain, cravings, fatigue after meals, or difficulty losing weight despite eating less
Excessive use, such as binge drinking (four drinks for women, five for men in one sitting), exacerbates these risks
Longevity and vital aging are two aspects of life that go hand in hand
Zepbound May Be Better If: Maximum weight loss is your primary goal SURMOUNT-5 clearly favours it You want more dose flexibility (six strengths to fine-tune tolerance) You also have moderate-to-severe obstructive sleep apnoea with obesity You prefer the cheaper self-drawn vial option via LillyDirect Wegovy May Be Better If: You have established cardiovascular disease Wegovy has an FDA-approved indication to reduce heart attack and stroke risk You dislike injections the oral tablet is now available Your insurance covers Wegovy but not Zepbound (it has been on the market longer and is on more formularies) You respond well to GLP-1-only therapy and tolerate it comfortably What Both Require: Neither drug works in isolation
